Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008777 | 0.88 | MAOB (0.47) | CNR2ALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL20349586 | 0.88 | ALDH1A1 (0.47) | CNR2ALDH1A1MAPK1TSHRTDP1 | |
| SCHEMBL9325952 | 0.85 | ALDH1A1 (0.45) | ALDH1A1MAPK1TSHRTDP1L3MBTL1 | |
| SCHEMBL9692544 | 0.84 | KMT2A (0.51) | CNR2ALDH1A1MAPK1TSHRTDP1 | |
| SCHEMBL3507981 | 0.84 | NPC1 (0.49) | CNR2MAPK1TSHRCES2CES1 | |
| SCHEMBL20349587 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPK1TSHRTDP1L3MBTL1 | |
| SCHEMBL4138316 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPK1TSHRTDP1L3MBTL1 | |
| SCHEMBL9076689 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPK1TSHRTDP1L3MBTL1 | |
| SCHEMBL2011761 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPK1TSHRTDP1L3MBTL1 | |
| SCHEMBL9326581 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPK1TSHRTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718285-B1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-16 | — | — | EP | disclosed |
| EP-2718285-B1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-16 | — | — | EP | disclosed |
| US-9193704-B2 | Hydantoin derivatives as KV3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9193704-B2 | Hydantoin derivatives as KV3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9193704-B2 | Hydantoin derivatives as KV3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| EP-2718285-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012168710-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-12-13 | — | — | WO | disclosed |
| EP-1585733-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | disclosed |
| WO-2004094430-A1 | TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093809-A2 | SUBSTITUTED ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS, CANCER AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004080376-A2 | HYDROXYETHYLAMINE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY FOR THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004063166-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | HSD17B10, IDH2, INSR | CNR2 337/4885ALDH1A1 135/4885MAPK1 663/4885 |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | CNR2 621/4885ALDH1A1 1858/4885MAPK1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.